| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Departments of Neurology (Dr. Kälviäinen), Ophthalmology (Drs. Nousiainen and Mäntyjärvi), Neurophysiology (Dr. Partanen), and Radiology (Dr. Partanen), University Hospital of Kuopio; Department of Ophthalmology (Dr. Nikoskelainen), University Hospital of Turku; and A.I. Virtanen Institute (Dr. Riekkinen), University of Kuopio, Finland.
Address correspondence and reprint requests to Dr. Reetta Kälviäinen, Department of Neurology, University Hospital of Kuopio, POB 1777, 70211 Kuopio, Finland; e-mail: reetta.kalviainen{at}kuh.fi
OBJECTIVE: To determine whether there is a causal link between vigabatrin treatment and concentric visual field defects and to evaluate the prevalence of these visual field constrictions.
BACKGROUND: While the GABAergic antiepileptic drug (AED) vigabatrin was being clinically developed, only rare cases (less than 1:1000) of symptomatic visual field constriction and retinal disorders were reported. During 1997 to 1998, concentric visual field constrictions were described in case reports of mostly drug-resistant epilepsy patients receiving vigabatrin concurrently with other AEDs.
METHODS: Ophthalmologic tests including Goldmann perimetry were performed on 32 adult patients on long-term successful vigabatrin monotherapy (treatment duration 29 to 119 months) and on 18 patients on carbamazepine monotherapy (treatment duration 32 to 108 months). Eighteen healthy adults served as controls.
RESULTS: None of the patients complained about vision problems when asked to participate into the study. Thirteen out of the 32 (40%) epilepsy patients treated with vigabatrin monotherapy had concentrically constricted visual fields (9% severely, 31% mildly constricted), whereas none of the carbamazepine monotherapy patients or normal controls presented with a visual field defect (chi-square test, p = 0.0001). The extents of the visual fields were significantly constricted in vigabatrin group as compared with the visual fields of the patients in carbamazepine group or healthy controls (analysis of variance, Scheffé F-test, significant at 99%).
CONCLUSIONS: The use of vigabatrin seems to increase the risk of a unique and specific pattern of bilateral, mainly asymptomatic visual field constriction. This risk should be considered when using vigabatrin. Visual field testing should also be performed before treatment and during routine follow-up for patients on vigabatrin.
Key words: Visual field defect—Vigabatrin—Antiepileptic drugs.
This article has been cited by other articles:
|
|
 |
|
  R. Werth and G. Schadler Visual field loss in young children and mentally handicapped adolescents receiving vigabatrin. Invest. Ophthalmol. Vis. Sci., July 1, 2006; 47(7): 3028 - 3035. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. I. Bekkelund, H. Lilleng, and S. Tonseth Gabapentin may cause reversible visual field constriction. BMJ, May 20, 2006; 332(7551): 1193 - 1193. [Full Text] [PDF]
|
|
|
|
|
|
J. M. Wild, C. R. Robson, A. L. Jones, I. A. Cunliffe, and P. E. M. Smith Detecting vigabatrin toxicity by imaging of the retinal nerve fiber layer. Invest. Ophthalmol. Vis. Sci., March 1, 2006; 47(3): 917 - 924. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Mecarelli, E. Vicenzini, P. Pulitano, N. Vanacore, F. S. Romolo, V. Di Piero, G. L. Lenzi, and N. Accornero Clinical, Cognitive, and Neurophysiologic Correlates of Short-Term Treatment with Carbamazepine, Oxcarbazepine, and Levetiracetam in Healthy Volunteers Ann. Pharmacother., November 1, 2004; 38(11): 1816 - 1822. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Kwan and M. J. Brodie Clinical trials of antiepileptic medications in newly diagnosed patients with epilepsy Neurology, June 10, 2003; 60(90114): S2 - 12. [Abstract] [Full Text]
|
|
|
|
 |
|
 E. Banin, R. S. Shalev, A. Obolensky, R. Neis, I. Chowers, and V. Gross-Tsur Retinal Function Abnormalities in Patients Treated With Vigabatrin Arch Ophthalmol, June 1, 2003; 121(6): 811 - 816. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.E.M. Smith and J.P. Leach Epilepsy: time for review QJM, February 1, 2003; 96(2): 87 - 89. [Full Text] [PDF]
|
|
|
|
 |
|
 A Nicolson, J P Leach, D W Chadwick, and D F Smith The legacy of vigabatrin in a regional epilepsy clinic J. Neurol. Neurosurg. Psychiatry, September 1, 2002; 73(3): 327 - 329. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. F.A. Harding, E. L. Spencer, J. M. Wild, M. Conway, and R. L. Bohn Field-specific visual-evoked potentials: Identifying field defects in vigabatrin-treated children Neurology, April 23, 2002; 58(8): 1261 - 1265. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Nousiainen, M. Mantyjarvi, and R. Kalviainen No reversion in vigabatrin-associated visual field defects Neurology, November 27, 2001; 57(10): 1916 - 1917. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Sills, P.N. Patsalos, E. Butler, G. Forrest, N. Ratnaraj, and M.J. Brodie Visual field constriction: Accumulation of vigabatrin but not tiagabine in the retina Neurology, July 24, 2001; 57(2): 196 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Ravindran, P Blumbergs, J Crompton, G Pietris, and H Waddy Visual field loss associated with vigabatrin: pathological correlations J. Neurol. Neurosurg. Psychiatry, June 1, 2001; 70(6): 787 - 789. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A G MARSON and D W CHADWICK New drug treatments for epilepsy J. Neurol. Neurosurg. Psychiatry, February 1, 2001; 70(2): 143 - 147. [Full Text] [PDF]
|
|
|
|
|
|
A. LUCHETTI, A. AMADI, G. GOBBI, and G. BERTANI Visual field defects associated with vigabatrin monotherapy in children J. Neurol. Neurosurg. Psychiatry, October 1, 2000; 69(4): 566 - 566. [Full Text]
|
|
|
|
|
|
N. R. Miller Using the electroretinogram to detect and monitor the retinal toxicity of anticonvulsants Neurology, August 8, 2000; 55(3): 333 - 334. [Full Text] [PDF]
|
|
|
|
|
|
G. F. A. Harding, J. M. Wild, K. A. Robertson, S. Rietbrock, and C. Martinez Separating the retinal electrophysiologic effects of vigabatrin: Treatment versus field loss Neurology, August 8, 2000; 55(3): 347 - 352. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Johnson, G. L. Krauss, N. R. Miller, M. Medura, and S. R. Paul Visual function loss from vigabatrin: Effect of stopping the drug Neurology, July 12, 2000; 55(1): 40 - 45. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Nousiainen, R. Kälviäinen, and M. Mäntyjärvi Contrast and glare sensitivity in epilepsy patients treated with vigabatrin or carbamazepine monotherapy compared with healthy volunteers Br J Ophthalmol, June 1, 2000; 84(6): 622 - 625. [Abstract] [Full Text]
|
|
|
|
|
|
I F Comaish, C Gorman, N R Galloway, K. Manuchehri, A. Midelfart, and L V Wilton Visual field defect associated with vigabatrin BMJ, May 20, 2000; 320(7246): 1403 - 1403. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
